2,4-Imidazolidinedione, 5-[[4-[4-hydroxy-3-(1-methylethyl)phenoxy]-3,5-diiodophenyl]methyl]- manufacturers
- CO23
-
- $233.00 / 1mg
-
2024-11-19
- CAS:1370363-74-8
- Min. Order:
- Purity: 96.52%
- Supply Ability: 10g
- CO23
-
- $233.00 / 1mg
-
2024-11-19
- CAS:1370363-74-8
- Min. Order:
- Purity: 96.52%
- Supply Ability: 10g
|
| | 2,4-Imidazolidinedione, 5-[[4-[4-hydroxy-3-(1-methylethyl)phenoxy]-3,5-diiodophenyl]methyl]- Basic information |
| | 2,4-Imidazolidinedione, 5-[[4-[4-hydroxy-3-(1-methylethyl)phenoxy]-3,5-diiodophenyl]methyl]- Chemical Properties |
| density | 1.878±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 8.70±0.10(Predicted) | | color | Off-white to light yellow |
| | 2,4-Imidazolidinedione, 5-[[4-[4-hydroxy-3-(1-methylethyl)phenoxy]-3,5-diiodophenyl]methyl]- Usage And Synthesis |
| Uses | CO23 is a selective thyroid hormone receptor (TR) α agonist and used for growth and development regulation. CO23 was able to be transported through the blood-brain barrier[1]. | | in vivo | CO23 (ip; 0.04-5.0 nmol/g) has ≈50% cholesterol reduction with 0.8 nmol/g dose and higher doses are equally effective. CO23 has no effect at the lowest dose of 0.04 nmol/g and increases Dio1 mRNA 5-, 10-, and 15-fold at the doses of 0.8, 2.5, and 5 nmol/g, respectively[1]. | Animal Model: | Hypothyroid Wistar rats[1] | | Dosage: | 0.04, 0.8, 2.5, and 5.0 nmol/g | | Administration: | Ip | | Result: | Had ≈50% cholesterol reduction with 0.8 nmol/g dose and higher doses were equally effective.
|
| | References | [1] Grijota-Martínez C, et al. In vivo activity of the thyroid hormone receptor beta- and α-selective agonists GC-24 and CO23on rat liver, heart, and brain. Endocrinology. 2011 Mar;152(3):1136-42. DOI:10.1210/en.2010-0813 |
| | 2,4-Imidazolidinedione, 5-[[4-[4-hydroxy-3-(1-methylethyl)phenoxy]-3,5-diiodophenyl]methyl]- Preparation Products And Raw materials |
|